Boston Scientific’s third-quarter 2020 revenue total is higher than Wall Street analysts expected it to be, but it is still lower than it was a year ago due to the slowdown in procedures caused by the pandemic.
The company generated nearly $2.7bn in sales during the third quarter of 2020, representing a 2.5% decline on an operational...







